Results 131 to 140 of about 58,868 (161)
Some of the next articles are maybe not open access.

Genome-Based Characterization of Plant-Associated Rhodococcus qingshengii RL1 Reveals Stress Tolerance and Plant–Microbe Interaction Traits

open access: yesFrontiers in Microbiology, 2021
Stress tolerant, plant-associated bacteria can play an important role in maintaining a functional plant microbiome and protecting plants against various (a)biotic stresses.
Theresa Kuhl   +2 more
exaly   +2 more sources

Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG.

Journal of Clinical Oncology, 2023
495 Background: Patients (pts) with BCG-unresponsive NMIBC have limited treatment options and are at an increased risk for cystectomy. Nogapendekin alfa inbakicept (NAI, also known as N-803), is an interleukin-15 superagonist (IL-15RαFc), which ...
K. Chamie   +6 more
semanticscholar   +1 more source

Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers

Journal of Immunology, 2022
Key Points Healthy volunteers were treated with N-803, an IL-15 superagonist. N-803 was safe and had predictable pharmacokinetics. N-803 mediated robust pharmacodynamic effects on CD8+ T cells and NK cells.
M. Rubinstein   +16 more
semanticscholar   +1 more source

The wall-associated kinase-like gene RL1 contributes to red leaves in sorghum.

The Plant Journal, 2022
Red leaves are common in trees but rare in cereal crops. Red leaves can be used as raw materials for anthocyanin extraction and may have some adaptive significance for plants.
Ya Lv   +9 more
semanticscholar   +1 more source

PLLBA-01 FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS

Journal of Urology, 2022
INTRODUCTION AND OBJECTIVE: Patients with NMIBC CIS unresponsive to BCG have limited treatment options. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that promotes proliferation and activation of natural ...
Sam Chang   +6 more
semanticscholar   +1 more source

Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

Journal of Clinical Oncology, 2022
582 Background: Pancreatic cancer claimed an estimated 47,050 lives in the USA in 2020, with an expected median overall survival (OS) of 3 months in 3rd line. (Manax ASCO GI 2019), with no evidence of disease control in these late stage patients.
T. Seery   +6 more
semanticscholar   +1 more source

Insight Into Metabolic Versatility of an Aromatic Compounds-Degrading Arthrobacter sp. YC-RL1

open access: yesFrontiers in Microbiology, 2018
The genus Arthrobacter is ubiquitously distributed in different natural environments. Many xenobiotic-degrading Arthrobacter strains have been isolated and described; however, few have been systematically characterized with regard to multiple ...
Lei Ren, Yanchun Yan
exaly   +2 more sources

Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.

, 2021
510Background: Patients with NMIBC CIS unresponsive to BCG have limited treatment options. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL-15RαFc) that promotes...
K. Chamie   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy